ARTICLE | Clinical News
DRM04: Phase III data
October 10, 2016 7:00 AM UTC
Top-line data from the double-blind, U.S. Phase III ATMOS-2 trial in 353 patients with primary axillary hyperhidrosis showed that once-daily 3.75% topical DRM04 met the co-primary endpoints of a great...